Progress and potential of non-inhibitory small molecule chaperones for the treatment of Gaucher disease and its implications for Parkinson disease

References

• De Duve C, Pressman BC, Gianetto R, et al. Tissue fractionation studies. 6. Intracellular distribution patterns of enzymes in rat-liver tissue. Biochem J. 1955;60(4):604–617.
   PubMed Web of Science ®Google Scholar
• De Duve C. The lysosome turns fifty. Nat Cell Biol. 2005;7(9):847–849.
   PubMed Web of Science ®Google Scholar
• Kaushik S, Cuervo AM. Chaperone-mediated autophagy: a unique way to enter the lysosome world. Trends Cell Biol. 2012;22(8):407–417.
   PubMed Web of Science ®Google Scholar
• Luzio JP, Parkinson MD, Gray SR, et al. The delivery of endocytosed cargo to lysosomes. Biochem Soc Trans. 2009;37(Pt 5):1019–1021.
   PubMed Web of Science ®Google Scholar
• Mijaljica D, Prescott M, Devenish RJ. Microautophagy in mammalian cells: revisiting a 40-year-old conundrum. Autophagy. 2011;7(7):673–682.
   PubMed Web of Science ®Google Scholar
• Mizushima N, Levine B, Cuervo AM, et al. Autophagy fights disease through cellular self-digestion. Nature. 2008;451(7182):1069–1075.
   PubMed Web of Science ®Google Scholar
• Saftig P. Lysosomes. Georgetown (TX): Landes Bioscience/Eurekah.com; Springer Science+Business Media; 2005.
   Google Scholar
• Settembre C, Ballabio A. Lysosomal adaptation: how the lysosome responds to external cues. Cold Spring Harb Perspect Biol. 2014;6:(6). pii: a016907.
   PubMed Web of Science ®Google Scholar
• Sardiello M, Palmieri M, Di Ronza A, et al. A gene network regulating lysosomal biogenesis and function. Science. 2009;325(5939):473–477.
   PubMed Web of Science ®Google Scholar
• Settembre C, Di Malta C, Polito VA, et al. TFEB links autophagy to lysosomal biogenesis. Science. 2011;332(6036):1429–1433.
   PubMed Web of Science ®Google Scholar
• Schulze H, Kolter T, Sandhoff K. Principles of lysosomal membrane degradation: cellular topology and biochemistry of lysosomal lipid degradation. Biochim Biophys Acta. 2009;1793(4):674–683.
   PubMed Web of Science ®Google Scholar
• Roczniak-Ferguson A, Petit CS, Froehlich F, et al. The transcription factor TFEB links mTORC1 signaling to transcriptional control of lysosome homeostasis. Sci Signal. 2012;5(228):ra42.
   PubMed Web of Science ®Google Scholar
• Settembre C, Zoncu R, Medina DL, et al. A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB. Embo J. 2012;31(5):1095–1108.
   PubMed Web of Science ®Google Scholar
• Martina JA, Chen Y, Gucek M, et al. MTORC1 functions as a transcriptional regulator of autophagy by preventing nuclear transport of TFEB. Autophagy. 2012;8(6):903–914.
   PubMed Web of Science ®Google Scholar
• Settembre C, De Cegli R, Mansueto G, et al. TFEB controls cellular lipid metabolism through a starvation-induced autoregulatory loop. Nat Cell Biol. 2013;15(6):647–658.
   PubMed Web of Science ®Google Scholar
• Beutler E, Grabowski GA. Gaucher disease. In: Scriver CBA, AL B, WS S, et al., editors. The metabolic & molecular bases of inherited disease. New York: McGraw-Hill; 2001. p. 3635–3668.
   Google Scholar
• Lachmann RH, Grant IR, Halsall D, et al. Twin pairs showing discordance of phenotype in adult Gaucher’s disease. QJM. 2004;97(4):199–204.
   PubMed Web of Science ®Google Scholar
• Sidransky E. Gaucher disease: insights from a rare Mendelian disorder. Discov Med. 2012;14(77):273–281.
   PubMed Web of Science ®Google Scholar
• Pastores GM, Patel MJ, Firooznia H. Bone and joint complications related to Gaucher disease. Curr Rheumatol Rep. 2000;2(2):175–180.
   PubMedGoogle Scholar
• Sidransky E. Gaucher disease: complexity in a “simple” disorder. Mol Genet Metab. 2004;83(1–2):6–15.
   PubMed Web of Science ®Google Scholar
• Gupta N, Oppenheim IM, Kauvar EF, et al. Type 2 Gaucher disease: phenotypic variation and genotypic heterogeneity. Blood Cells Mol Dis. 2011;46(1):75–84.
   PubMed Web of Science ®Google Scholar
• Sidransky E, Lopez G. The link between the GBA gene and parkinsonism. Lancet Neurol. 2012;11(11):986–998.
   PubMed Web of Science ®Google Scholar
• Goker-Alpan O, Hruska KS, Orvisky E, et al. Divergent phenotypes in Gaucher disease implicate the role of modifiers. J Med Genet. 2005;42(6):e37.
   PubMed Web of Science ®Google Scholar
• Hruska KS, LaMarca ME, Scott CR, et al. Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Hum Mutat. 2008;29(5):567–583.
   PubMed Web of Science ®Google Scholar
• Biegstraaten M, Van Schaik IN, Aerts JM, et al. A monozygotic twin pair with highly discordant Gaucher phenotypes. Blood Cells Mol Dis. 2011;46(1):39–41.
   PubMed Web of Science ®Google Scholar
• Tayebi N, Callahan M, Madike V, et al. Gaucher disease and parkinsonism: a phenotypic and genotypic characterization. Mol Genet Metab. 2001;73(4):313–321.
   PubMed Web of Science ®Google Scholar
• Bembi B, Zambito Marsala S, Sidransky E, et al. Gaucher’s disease with Parkinson’s disease: clinical and pathological aspects. Neurology. 2003;61(1):99–101.
   PubMed Web of Science ®Google Scholar
• Tayebi N, Walker J, Stubblefield B, et al. Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism? Mol Genet Metab. 2003;79(2):104–109.
   PubMed Web of Science ®Google Scholar
• Goker-Alpan O, Schiffmann R, LaMarca ME, et al. Parkinsonism among Gaucher disease carriers. J Med Genet. 2004;41(12):937–940.
   PubMed Web of Science ®Google Scholar
• Lwin A, Orvisky E, Goker-Alpan O, et al. Glucocerebrosidase mutations in subjects with parkinsonism. Mol Genet Metab. 2004;81(1):70–73.
   PubMed Web of Science ®Google Scholar
• Eblan MJ, Nguyen J, Ziegler SG, et al. Glucocerebrosidase mutations are also found in subjects with early-onset parkinsonism from Venezuela. Move Disord. 2006;21(2):282–283.
   PubMed Web of Science ®Google Scholar
• Ziegler SG, Eblan MJ, Gutti U, et al. Glucocerebrosidase mutations in Chinese subjects from Taiwan with sporadic Parkinson disease. Mol Genet Metab. 2007;91(2):195–200.
   PubMed Web of Science ®Google Scholar
• Sidransky E, Nalls MA, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson’s disease. N Engl J Med. 2009;361(17):1651–1661.
   PubMed Web of Science ®Google Scholar
• Siebert M, Sidransky E, Westbroek W. Glucocerebrosidase is shaking up the synucleinopathies. Brain. 2014;137(Pt 5):1304–1322.
   PubMed Web of Science ®Google Scholar
• Malec-Litwinowicz M, Rudzinska M, Szubiga M, et al. Cognitive impairment in carriers of glucocerebrosidase gene mutation in Parkinson disease patients. Neurol Neurochir Pol. 2014;48(4):258–261.
   PubMed Web of Science ®Google Scholar
• Pulkes T, Choubtum L, Chitphuk S, et al. Glucocerebrosidase mutations in Thai patients with Parkinson’s disease. Parkinsonism Relat Disord. 2014;20(9):986–991.
   PubMed Web of Science ®Google Scholar
• Nalls MA, Duran R, Lopez G, et al. A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol. 2013;70(6):727–735.
   PubMed Web of Science ®Google Scholar
• Mitsui J, Matsukawa T, Sasaki H, et al. Variants associated with Gaucher disease in multiple system atrophy. Ann Clin Transl Neurol. 2015;2(4):417–426.
   PubMed Web of Science ®Google Scholar
• De Duve C. From lysosomes to storage diseases and back: a personal reminiscence. In: Barranger JA, Cabrera-Salazar MA, editors. Lysosomal storage disorders. New York: Springer; 2007. p. 1–5.
   Google Scholar
• Brady RO, Pentchev PG, Gal AE, et al. Replacement therapy for inherited enzyme deficiency. Use of purified glucocerebrosidase in Gaucher’s disease. N Engl J Med. 1974;291(19):989–993.
   PubMed Web of Science ®Google Scholar
• Barton NW, Furbish FS, Murray GJ, et al. Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease. Proc Natl Acad Sci. 1990;87(5):1913–1916.
   PubMed Web of Science ®Google Scholar
• Doneda D, Netto CB, Moulin CC, et al. Effects of imiglucerase on the growth and metabolism of Gaucher disease type I patients: a systematic review. Nutr Metab (Lond). 2013;10:34.
   PubMed Web of Science ®Google Scholar
• Morris JL. Velaglucerase Alfa for the management of type 1 Gaucher disease. Clin Ther. 2012;34(2):259–271.
   PubMed Web of Science ®Google Scholar
• Grabowski GA, Hopkin RJ. Enzyme therapy for lysosomal storage disease: principles, practice, and prospects. Annu Rev Genomics Hum Genet. 2003;4(1):403–436.
   PubMed Web of Science ®Google Scholar
• Valayannopoulos V. Chapter 190 - Enzyme replacement therapy and substrate reduction therapy in lysosomal storage disorders with neurological expression. In: Olivier Dulac ML, Harvey BS, editors. Handbook of clinical neurology. Amsterdam: Elsevier; 2013. p. 1851–1857.
   Google Scholar
• Gramlich PA, Westbroek W, Feldman RA, et al. A peptide-linked recombinant glucocerebrosidase for targeted neuronal delivery: design, production, and assessment. J Biotechnol. 2016;221:1–12.
   PubMed Web of Science ®Google Scholar
• Henley WE, Anderson LJ, Wyatt KM, et al. The NCS-LSD cohort study: a description of the methods and analyses used to assess the long-term effectiveness of enzyme replacement therapy and substrate reduction therapy in patients with lysosomal storage disorders. J Inherit Metab Dis. 2014;37(6):939–944.
   PubMed Web of Science ®Google Scholar
• Alfonso P, Pampín S, Estrada J, et al. Miglustat (NB-DNJ) works as a chaperone for mutated acid β-glucosidase in cells transfected with several Gaucher disease mutations. Blood Cells Mol Dis. 2005;35(2):268–276.
   PubMed Web of Science ®Google Scholar
• Andrade MM, Medrano B, Alfonso P, et al. Substrate reduction therapy with Miglustat in type 1 Gaucher disease in Spain. Nine years outcomes update on ZAGAL study. Blood. 2013;122(21):4713.
   Google Scholar
• Schiffmann R, Fitzgibbon EJ, Harris C, et al. Randomized, controlled trial of miglustat in Gaucher’s disease type 3. Ann Neurol. 2008;64(5):514–522.
   PubMed Web of Science ®Google Scholar
• Marshall J, Sun Y, Bangari DS, et al. CNS-accessible inhibitor of glucosylceramide synthase for substrate reduction therapy of neuronopathic Gaucher disease. Mol Ther. 2016 [Mar 7]. [Epub ahead of print]
   Google Scholar
• Scott L. Eliglustat: a review in Gaucher disease type 1. Drugs. 2015;75(14):1669–1678.
   PubMed Web of Science ®Google Scholar
• Balwani M, Burrow TA, Charrow J, et al. Recommendations for the use of eliglustat in the treatment of adults with Gaucher disease type 1 in the United States. Mol Genet Metab. 2016;117(2):95–103.
   PubMed Web of Science ®Google Scholar
• Bennett LL, Turcotte K. Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease. Drug Des Devel Ther. 2015;9:4639–4647.
   PubMed Web of Science ®Google Scholar
• Pastores GM, Hughes DA. Gaucher disease. GeneReviews. 2000 (updated 2015). Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Fong CT, Mefford HC, Smith RJH, Stephens K, editors. Seattle (WA): University of Washington.
   Google Scholar
• Ficicioglu C. Review of mglustat for clinical management in Gaucher disease type 1. Ther Clin Risk Manag. 2008;4(2):425–431.
   PubMedGoogle Scholar
• Dahl M, Doyle A, Olsson K, et al. Lentiviral gene therapy using cellular promoters cures type 1 Gaucher disease in mice. Mol Ther. 2015;23(5):835–844.
   PubMed Web of Science ®Google Scholar
• Compain P, Martin OR, Boucheron C, et al. Design and synthesis of highly potent and selective pharmacological chaperones for the treatment of Gaucher’s disease. Chem Bio Chem. 2006;7(9):1356–1359.
   Web of Science ®Google Scholar
• Lieberman RL, Wustman BA, Huertas P, et al. Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease. Nat Chem Biol. 2007;3(2):101–107.
   PubMed Web of Science ®Google Scholar
• Meusser B, Hirsch C, Jarosch E, et al. ERAD: the long road to destruction. Nat Cell Biol. 2005;7(8):766–772.
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Ichinomiya S, Kurosawa M, et al. Chemical chaperone therapy: clinical effect in murine G(M1)-gangliosidosis. Ann Neurol. 2007;62(6):671–675.
   PubMed Web of Science ®Google Scholar
• Takamura A, Higaki K, Ninomiya H, et al. Lysosomal accumulation of Trk protein in brain of GM(1) -gangliosidosis mouse and its restoration by chemical chaperone. J Neurochem. 2011;118(3):399–406.
   PubMed Web of Science ®Google Scholar
• Takamura A, Higaki K, Kajimaki K, et al. Enhanced autophagy and mitochondrial aberrations in murine G(M1)-gangliosidosis. Biochem Biophys Res Commun. 2008;367(3):616–622.
   PubMed Web of Science ®Google Scholar
• Maegawa GH, Tropak MB, Buttner JD, et al. Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease. J Biol Chem. 2009;284(35):23502–23516.
   PubMed Web of Science ®Google Scholar
• Luan Z, Li L, Higaki K, et al. The chaperone activity and toxicity of ambroxol on Gaucher cells and normal mice. Brain Dev. 2013;35(4):317–322.
   PubMed Web of Science ®Google Scholar
• Patnaik S, Zheng W, Choi JH, et al. Discovery, structure-activity relationship, and biological evaluation of noninhibitory small molecule chaperones of glucocerebrosidase. J Med Chem. 2012;55(12):5734–5748.
   PubMed Web of Science ®Google Scholar
• Sánchez-Ollé G, Duque J, Egido-Gabás M, et al. Promising results of the chaperone effect caused by iminosugars and aminocyclitol derivatives on mutant glucocerebrosidases causing Gaucher disease. Blood Cell Mol Dis. 2009;42(2):159–166.
   PubMed Web of Science ®Google Scholar
• Sawkar AR, Cheng W-C, Beutler E, et al. Chemical chaperones increase the cellular activity of N370S β-glucosidase: a therapeutic strategy for Gaucher disease. Proc Natl Acad Sci. 2002;99(24):15428–15433.
   PubMed Web of Science ®Google Scholar
• Gloster TM, Davies GJ. Glycosidase inhibition: assessing mimicry of the transition state. Org Biomol Chem. 2010;8(2):305–320.
   PubMed Web of Science ®Google Scholar
• Butters TD, Dwek RA, Platt FM. Imino sugar inhibitors for treating the lysosomal glycosphingolipidoses. Glycobiology. 2005;15(10):43R–52R.
   PubMed Web of Science ®Google Scholar
• Babajani G, Tropak MB, Mahuran DJ, et al. Pharmacological chaperones facilitate the post-ER transport of recombinant N370S mutant β-glucocerebrosidase in plant cells: Evidence that N370S is a folding mutant. Mol Genet Metab. 2012;106(3):323–329.
   PubMed Web of Science ®Google Scholar
• Khanna R, Benjamin ER, Pellegrino L, et al. The pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of beta-glucosidase. Febs J. 2010;277(7):1618–1638.
   PubMed Web of Science ®Google Scholar
• Sun Y, Liou B, Xu YH, et al. Ex vivo and in vivo effects of isofagomine on acid beta-glucosidase variants and substrate levels in Gaucher disease. J Biol Chem. 2012;287(6):4275–4287.
   PubMed Web of Science ®Google Scholar
• Sun Y, Ran H, Liou B, et al. Isofagomine in vivo effects in a neuronopathic Gaucher disease mouse. PLoS ONE. 2011;6(4):e19037.
   PubMed Web of Science ®Google Scholar
• Panicker LM, Miller D, Park TS, et al. Induced pluripotent stem cell model recapitulates pathologic hallmarks of Gaucher disease. Proc Natl Acad Sci U S A. 2012;109(44):18054–18059.
   PubMed Web of Science ®Google Scholar
• Zimran A. How I treat Gaucher disease. Blood. 2011;118(6):1463–1471.
   PubMed Web of Science ®Google Scholar
• Mena-Barragán T, García-Moreno MI, Nanba E, et al. Inhibitor versus chaperone behaviour of d-?fagomine, DAB and LAB sp2-iminosugar conjugates against glycosidases: A structure–activity relationship study in Gaucher fibroblasts. Eur J Med Chem 2015. pii:S0223-5234(15)30222-1. doi:10.1016/j.ejmech.2015.08.038.
   Google Scholar
• Luan Z, Higaki K, Aguilar-Moncayo M, et al. A fluorescent sp2-iminosugar with pharmacological chaperone activity for Gaucher disease: synthesis and intracellular distribution studies. Chem Bio Chem. 2010;11(17):2453–2464.
   Web of Science ®Google Scholar
• Marugan JJ, Zheng W, Motabar O, et al. Evaluation of Quinazoline analogues as Glucocerebrosidase inhibitors with chaperone activity. J Med Chem. 2011;54(4):1033–1058.
   PubMed Web of Science ®Google Scholar
• Bendikov-Bar I, Maor G, Filocamo M, et al. Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase. Blood Cells Mol Dis. 2013;50(2):141–145.
   PubMed Web of Science ®Google Scholar
• Zimran A, Altarescu G, Elstein D. Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease. Blood Cells, Molecules, and Diseases. 2013;50(2):134–137.
   PubMed Web of Science ®Google Scholar
• Lee B, Scaglia F. Inborn errors of metabolism: from neonatal screening to metabolic pathways. New York (NY): Oxford University Press; 2014.
   Google Scholar
• Zheng W, Padia J, Urban DJ, et al. Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher disease. Proc Natl Acad Sci U S A. 2007;104(32):13192–13197.
   PubMed Web of Science ®Google Scholar
• Goldin E, Zheng W, Motabar O, et al. High throughput screening for small molecule therapy for Gaucher disease using patient tissue as the source of Mutant Glucocerebrosidase. PLoS ONE. 2012;7(1):e29861.
   PubMed Web of Science ®Google Scholar
• Rogers S, Patnaik S, Schoenen F, et al. Discovery, SAR, and biological evaluation of non-inhibitory chaperones of Glucocerebrosidase. Bethesda (MD): Probe Reports from the NIH Molecular Libraries Program; 2010.
   Google Scholar
• Lee RE. The fine structure of the cerebroside occurring in Gaucher’s disease. Proc Natl Acad Sci U S A. 1968;61(2):484–489.
   PubMed Web of Science ®Google Scholar
• Aflaki E, Stubblefield BK, Maniwang E, et al. Macrophage models of Gaucher disease for evaluating disease pathogenesis and candidate drugs. Sci Transl Med. 2014;6(240):240ra73–ra73.
   PubMed Web of Science ®Google Scholar
• Yang C, Rahimpour S, Lu J, et al. Histone deacetylase inhibitors increase glucocerebrosidase activity in Gaucher disease by modulation of molecular chaperones. Proc Natl Acad Sci U S A. 2013;110(3):966–971.
   PubMed Web of Science ®Google Scholar
• Yang C, Wang H, Zhu D, et al. Mutant glucocerebrosidase in Gaucher disease recruits Hsp27 to the Hsp90 chaperone complex for proteasomal degradation. Proc Natl Acad Sci U S A. 2015;112(4):1137–1142.
   PubMed Web of Science ®Google Scholar
• Witte MD, Kallemeijn WW, Aten J, et al. Ultrasensitive in situ visualization of active glucocerebrosidase molecules. Nat Chem Biol. 2010;6(12):907–913.
   PubMed Web of Science ®Google Scholar
• Yadav AK, Shen DL, Shan X, et al. Fluorescence-Quenched substrates for live cell imaging of human Glucocerebrosidase activity. J Am Chem Soc. 2015;137(3):1181–1189.
   PubMed Web of Science ®Google Scholar
• Lee HW, Heo CH, Sen D, et al. Ratiometric two-photon fluorescent probe for quantitative detection of β-Galactosidase activity in senescent cells. Anal Chem. 2014;86(20):10001–10005.
   PubMed Web of Science ®Google Scholar
• Cook C, Stetler C, Petrucelli L. Disruption of protein quality control in Parkinson’s disease. Cold Spring Harb Perspect Med. 2012;2(5):a009423.
   PubMed Web of Science ®Google Scholar
• Arias E, Cuervo AM. Chaperone-mediated autophagy in protein quality control. Curr Opin Cell Biol. 2011;23(2):184–189.
   PubMed Web of Science ®Google Scholar
• Yang Z, Klionsky DJ. Eaten alive: a history of macroautophagy. Nat Cell Biol. 2010;12(9):814–822.
   PubMed Web of Science ®Google Scholar
• Lu M, Sun XL, Qiao C, et al. Uncoupling protein 2 deficiency aggravates astrocytic endoplasmic reticulum stress and nod-like receptor protein 3 inflammasome activation. Neurobiol Aging. 2014;35(2):421–430.
   Web of Science ®Google Scholar
• Tofaris GK. Lysosome-dependent pathways as a unifying theme in Parkinson’s disease. Mov Disord. 2012;27(11):1364–1369.
   PubMed Web of Science ®Google Scholar
• Schultheis PJ, Fleming SM, Clippinger AK, et al. Atp13a2-deficient mice exhibit neuronal ceroid lipofuscinosis, limited alpha-synuclein accumulation and age-dependent sensorimotor deficits. Hum Mol Genet. 2013;22(10):2067–2082.
   PubMed Web of Science ®Google Scholar
• Mazzulli JR, Xu YH, Sun Y, et al. Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell. 2011;146(1):37–52.
   PubMed Web of Science ®Google Scholar
• Cleeter MW, Chau KY, Gluck C, et al. Glucocerebrosidase inhibition causes mitochondrial dysfunction and free radical damage. Neurochem Int. 2013;62(1):1–7.
   PubMed Web of Science ®Google Scholar
• Cullen V, Sardi SP, Ng J, et al. Acid beta-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter alpha-synuclein processing. Annal Neurol. 2011;69(6):940–953.
   PubMed Web of Science ®Google Scholar
• Gegg ME, Burke D, Heales SJ, et al. Glucocerebrosidase deficiency in substantia nigra of Parkinson disease brains. Annal Neurol. 2012;72(3):455–463.
   PubMed Web of Science ®Google Scholar
• Manning-Boğ AB, Schüle B, Langston JW. Alpha-synuclein-glucocerebrosidase interactions in pharmacological Gaucher models: a biological link between Gaucher disease and parkinsonism. Neurotoxicology. 2009;30(6):1127–1132.
   PubMed Web of Science ®Google Scholar
• Osellame LD, Rahim AA, Hargreaves IP, et al. Mitochondria and quality control defects in a mouse model of Gaucher disease–links to Parkinson’s disease. Cell Metab. 2013;17(6):941–953.
   PubMed Web of Science ®Google Scholar
• Sardi SP, Clarke J, Kinnecom C, et al. CNS expression of glucocerebrosidase corrects alpha-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy. Proc Natl Acad Sci U S A. 2011;108(29):12101–12106.
   PubMed Web of Science ®Google Scholar
• Sardi SP, Clarke J, Viel C, et al. Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies. Proc Natl Acad Sci U S A. 2013;110(9):3537–3542.
   PubMed Web of Science ®Google Scholar
• Murphy KE, Halliday GM. Glucocerebrosidase deficits in sporadic Parkinson disease. Autophagy. 2014;10(7):1350–1351.
   PubMed Web of Science ®Google Scholar
• Chiasserini D, Paciotti S, Eusebi P, et al. Selective loss of glucocerebrosidase activity in sporadic Parkinson’s disease and dementia with Lewy bodies. Mol Neurodegener. 2015;10(1):15.
   PubMed Web of Science ®Google Scholar
• Du TT, Wang L, Duan CL, et al. GBA deficiency promotes SNCA/alpha-synuclein accumulation through autophagic inhibition by inactivated PPP2A. Autophagy. 2015;11(10):1803–1820.
   PubMed Web of Science ®Google Scholar
• Rocha EM, Smith GA, Park E, et al. Sustained systemic Glucocerebrosidase inhibition induces brain alpha-synuclein aggregation, microglia and complement C1q activation in mice. Antioxid Redox Signal. 2015;23(6):550–564.
   PubMed Web of Science ®Google Scholar
• McNeill A, Magalhaes J, Shen C, et al. Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. Brain. 2014;137(Pt 5):1481–1495.
   PubMed Web of Science ®Google Scholar
• Richter F, Fleming SM, Watson M, et al. A GCase chaperone improves motor function in a mouse model of synucleinopathy. Neurotherapeutics. 2014;11(4):840–856.
   PubMed Web of Science ®Google Scholar
• Dasgupta N, Xu Y-H, Li R, et al. Neuronopathic Gaucher disease: dysregulated mRNAs and miRNAs in brain pathogenesis and effects of pharmacologic chaperone treatment in a mouse model. Hum Mol Genet. 2015;24(24):7031–7048.
   PubMed Web of Science ®Google Scholar
• De La Mata M, Cotán D, Oropesa-Ávila M, et al. Pharmacological chaperones and coenzyme Q(10) treatment improves mutant β-Glucocerebrosidase activity and mitochondrial function in neuronopathic forms of Gaucher disease. Sci Rep. 2015;5:10903.
   PubMed Web of Science ®Google Scholar